 |
|
Investment Team
 Rick Blume, Managing Director
Rick Blume has been financing companies in healthcare for over three decades. His early investment banking career involved financing and banking relationships with hospitals, payers, physicians, and new biotech companies. The excitement he saw at Genentech, in its early years, led him to transition into venture capital in the mid 1980's. Blume co-founded CB Health Ventures in 1998 where he assembled what is now the core of Excel including Rico Petrillo, M.D., Steve Gullans, PhD, and Tricia Moriarty.
In each of his five venture funds he has followed the same successful strategy: invest broadly in healthcare across various sectors and stages and focus on businesses that lower costs and improve outcomes. By having savvy healthcare providers as limited partners and advisers, Blume has built up an extraordinary network to help with due diligence and market acceptance issues.
Blume has served as a director or active investor in many successful companies including Cytyc (acquired by Hologic - HOLX), AbT (now OSI - OSIP), Somatogen (acquired by Baxter - BAX), Edentec, Exact Sciences (EXAS), IPC The Hospitalist Company ( IPCM), GeneOhm (acquired by Becton Dickinson - BDX), Zonare, TransMedics, US Servis; and the former public health insurance company Washington National. Blume did his undergraduate studies at University of the Pacific and Stanford. His MBA is from Stanford University.
 Juan Enriquez, Managing Director
Mr. Enriquez was the founding Director of the Harvard Business School's Life Sciences Project. His best-selling book, As The Future Catches You, provided an early and accurate blue print of how a bio-based economy changes industries and corporations. He became an active angel investor, and then founded Biotechonomy Ventures, a successful fund that invested in highly promising life science companies such as BioTrove, a CB Health Ventures portfolio company, and Xcellerex. Throughout his career, Mr. Enriquez has successfully guided many companies - as CEO, director, investor, or president.
Most recently, he co-founded and led the financing for Drs. J. Craig Venter and Hamilton Smith's new company, Synthetic Genomics, Inc. He serves on numerous boards including Cabot Corporation (NYSE: CBT). He is also a world authority on the economic impact of life sciences on business, working directly with the CEOs of a number of Fortune Fifty companies, as well as various heads of state, on how to adapt to a world where the dominant language is shifting from the digital towards the language of life. He graduated from Harvard with a B.A. and an M.B.A., both with honors.
View Juan Enriquez's Selected Talks
Back to Top
 Steve Gullans, PhD, Managing Director
Dr. Gullans is an experienced investor, entrepreneur and scientist. Having worked with CB Health Ventures (CBHV) since its inception and with Dr. Petrillo since the mid 80's, Dr. Gullans has considerable first-hand experience with venture investing and entrepreneurship. As a Senior Advisor to CBHV, he worked closely with Dr. Petrillo and Mr. Blume to source deals, select portfolio company investments, assist in developing technologies, identify new markets, and assist with exits. In 2002, Dr. Gullans stepped in as a senior executive at US Genomics for two years to direct operations, recruit a new CEO, and assist with fundraising. In addition, with colleagues at Yale, he co-founded RxGen, Inc., a pharma services company where he served as CEO from 2004-2008. He also co-developed the technology that launched CellAct Pharma GmbH, a drug development company.
He is currently on the Board of Biocius and was a board member of BioTrove which was acquired by Life Technologies. He advises Aileron and US Genomics and formerly advised GeneOhm (acquired by Becton Dickinson - BDX) and other biotech companies.
Dr. Gullans is an expert in advanced life science technologies and was a faculty member at Harvard Medical School and Brigham and Women's Hospital for nearly 20 years. He has published more than 120 scientific papers in many leading journals, lectured internationally, and co-authored many patents. He received his B.S. at Union College, Ph.D. at Duke University, and postdoctoral training at the Yale School of Medicine.
Back to Top
 Enrico Petrillo, MD, Managing Director
Dr. Petrillo has a wealth of experience as a venture investor, healthcare consultant, entrepreneur, and physician that has been instrumental in the success of CB Health Ventures (CBHV), two funds which he co-founded with Mr. Blume. Dr. Petrillo has been advising and building successful healthcare and IT companies for over 20 years. He initiated investments in Aileron, MedVentive, US Genomics, BioTrove, Quovadx (now Healthvision), eBenX (acquired by SHPS), and Morphotek (acquired by Eisai). Dr. Petrillo has been a Director and/or an Observer at GeneOhm [acquired by Becton Dickinson - BDX ] , Exact [EXAS] , Aileron Therapeutics, MedVentive, BioTrove, U.S. Genomics, Morphotek, Quovadx, eBenX, TransMedics , and was a founder of Molecular Insight (MIPI). Previously he was a partner at Fletcher Spaght, a Boston-based consulting firm spun out of Boston Consulting Group that specializes in strategy and market consulting for multi-stage medical and IT companies. He is a current advisor to the Department of Defense, Office of the Secretary and affiliated agencies.
In addition to being a full time partner at Excel, Dr. Petrillo is an Adjunct Assistant Professor of Medicine at Boston University. Dr. Petrillo earned both his undergraduate and M.D. degrees from Tufts University, and completed his internship and residency at Harvard-affiliated hospitals in Boston.
Back to Top
 Caleb Winder, Vice President
Mr. Winder brings strong experience in healthcare, sales and marketing, finance and venture to the Excel team. Prior to joining Excel, he was a Principal at Biotechonomy Ventures, where he worked closely with Juan Enriquez to identify, finance, and manage several entrepreneurial ventures. In 2005, Mr. Winder assisted in the founding of Synthetic Genomics, Inc. including securing the initial and second financings of the company, and serving as the initial Director of Finance. Mr. Winder served as member of the board of Xcellerex, Inc which he and Mr. Enriquez restructured and drove to successful financings. Mr. Winder is a Board Observer at Dormir, MedVentive and Saladax Biomedical.
Mr. Winder spent his early career as an award-winning sales and marketing professional for companies that specialize in medical equipment, diagnostics systems, and software, including Midmark Corporation, Medical Graphics Corporation (acquired by Angeion), and Moldflow Corporation (acquired by Autodesk). Mr. Winder also worked in Business Development for GeneXP Biosciences (now Xceed Molecular) and is a member of the Entrepreneurial Council of the Wake Forest Translational Science Institute.
He received his M.B.A. from Babson College, magna cum laude, where he honored as a Babson Fellow in the Center for Technology Enterprise and was elected as Director of the Entrepreneurial Finance Group. He received a B.A. in Biology with a minor in Economics from Colby College.
Back to Top
|
|
